Saeed, Anwaar http://orcid.org/0000-0001-8024-9401
Park, Robin
Pathak, Harsh
Al-Bzour, Ayah Nedal http://orcid.org/0000-0001-8216-0400
Dai, Junqiang
Phadnis, Milind
Al-Rajabi, Raed
Kasi, Anup
Baranda, Joaquina http://orcid.org/0000-0002-0917-6307
Sun, Weijing http://orcid.org/0000-0001-6549-9605
Williamson, Stephen http://orcid.org/0000-0003-4118-1242
Chiu, Yu-Chiao http://orcid.org/0000-0003-1647-8634
Osmanbeyoglu, Hatice Ulku http://orcid.org/0000-0002-3175-1777
Madan, Rashna
Abushukair, Hassan http://orcid.org/0000-0002-0068-5201
Mulvaney, Kelly
Godwin, Andrew K. http://orcid.org/0000-0002-3987-9580
Saeed, Azhar
Funding for this research was provided by:
Exelixis
Article History
Received: 17 October 2023
Accepted: 31 January 2024
First Online: 20 February 2024
Competing interests
: A.S. reports a leadership role with Autem therapeutics, Exelixis, KAHR medical and Bristol-Myers Squibb; consulting or advisory board role with AstraZeneca, Bristol-Myers Squibb, Merck, Exelixis, Pfizer, Xilio therapeutics, Taiho, Amgen, Autem therapeutics, KAHR medical, and Daiichi Sankyo; institutional research funding from AstraZeneca, Bristol-Myers Squibb, Merck, Clovis, Exelixis, Actuate therapeutics, Incyte Corporation, Daiichi Sankyo, Five prime therapeutics, Amgen, Innovent biologics, Dragonfly therapeutics, Oxford Biotherapeutics, Arcus therapeutics, and KAHR medical; and participation as a data safety monitoring board chair for Arcus therapeutics. R.A. reports research grants (to institution) from AstraZeneca, Bayor, Merck, Bristol Myers Squibb, Exelixis, and Eureka Therapeutics and stock ownership in Actinium Pharmaceuticals and Seagen. A.K. reports research funding (to institution) from Astellas, Tesaro, and Bavarian Nordic. J.B. reports research grants (to institution) from Astellas, Chungchun Intellicrown, Impact Therapeutics, Poseida Therapeutics, Takeda Oncology, and Genome Co. and consultant fees (to institution) from Sanofi. S.W. reports stock/other ownership in Horizon Therapeutics, Iovance Biotherapeutics, and Merus and institutional research funding from Aleon Pharma, Astellas Pharma, Bayer Health, Bristol Myers Squibb, Daiichi Sankyo, EMD Serono, Merck Serono, Nektar, Novartis, Pharmacyclics, AbbVie, Regeneron, Rogosin Institute, Sanofi, Seagen, and Sotio. A.K.G. reports research funding from Predicine and VITRAC Therapeutics, is a co-founder of Sinochips Diagnostics, and serves as a scientific advisory board member to Biovica, Clara Biotech, and Sinochips Diagnostics. The remaining authors report no conflicts of interest.